AMISULPRIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H27N3O4S
Molecular Weight	369.479
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN1CCCC1CNC(=O)C2=C(OC)C=C(N)C(=C2)S(=O)(=O)CC

InChI

InChIKey=NTJOBXMMWNYJFB-UHFFFAOYSA-N

InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)

HIDE SMILES / InChI

Molecular Formula	C17H27N3O4S
Molecular Weight	369.479
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.sanofi.com.au/products/aus_pi_solian.pdf
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8996185 | https://www.ncbi.nlm.nih.gov/pubmed/19337725 | https://www.ncbi.nlm.nih.gov/pubmed/11735643

Amisulpride, a benzamide derivative, shows a unique therapeutic profile being atypical antipsychotic. At low doses, it enhances dopaminergic neurotransmission by preferentially blocking presynaptic dopamine D2/D3 autoreceptors. At higher doses, amisupride antagonises postsynaptic dopamine D2 and D3 receptors, preferentially in the limbic system rather than the striatum, thereby reducing dopaminergic transmission. In addition its antagonism at serotonin 5-HT7 receptors likely underlies the antidepressant actions. Amisulpride is approved for clinical use in treating schizophrenia in a number of European countries and also for treating dysthymia, a mild form of depression, in Italy.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D2 receptor 290 Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8996185 \| https://www.ncbi.nlm.nih.gov/pubmed/19337725	Antagonist 2737	2.8 nM [Ki]
Dopamine D3 receptor 89 Target ID: CHEMBL234 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8996185 \| https://www.ncbi.nlm.nih.gov/pubmed/19337725	Antagonist 2737	3.2 nM [Ki]
Serotonin 7 (5-HT7) receptor 31 Target ID: CHEMBL3155 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19337725	Antagonist 2737	11.5 nM [Ki]
Serotonin 2b (5-HT2b) receptor 60 Target ID: CHEMBL1833 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19337725	Antagonist 2737	13.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Schizophrenia 288 Sources: http://www.sanofi.com.au/products/aus_pi_solian.pdf	Primary		Approved 8307	SOLIAN Approved Use Amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

C_max

Value	Dose	Co-administered	Analyte	Population
586.3 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28793958	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		AMISULPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
5043.2 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28793958	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		AMISULPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
11.7 h REVIEW https://www.ncbi.nlm.nih.gov/pubmed/12404702	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		AMISULPRIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
6 g single, oral Overdose Dose: 6 g Route: oral Route: single Dose: 6 g Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	unhealthy, 29 years (range: 23-40 years) n = 23 Health Status: unhealthy Age Group: 29 years (range: 23-40 years) Sex: M+F Population Size: 23 Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	Other AEs: Bradycardia, Dystonic reaction... Other AEs: Bradycardia (24%) Dystonic reaction (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/20531221
6 g single, oral Overdose Dose: 6 g Route: oral Route: single Dose: 6 g Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	unhealthy, 29 years (range: 23-40 years) n = 49 Health Status: unhealthy Age Group: 29 years (range: 23-40 years) Sex: M+F Population Size: 49 Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	Other AEs: QT interval prolonged, Tachycardia... Other AEs: QT interval prolonged (64%) Tachycardia (23%) Sources: https://pubmed.ncbi.nlm.nih.gov/20531221
80 g single, oral Overdose Dose: 80 g Route: oral Route: single Dose: 80 g Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	unhealthy, 29 years (range: 23-40 years) n = 49 Health Status: unhealthy Age Group: 29 years (range: 23-40 years) Sex: M+F Population Size: 49 Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	Other AEs: Torsades de pointes... Other AEs: Torsades de pointes (7%) Sources: https://pubmed.ncbi.nlm.nih.gov/20531221
20 mg single, intravenous Highest studied dose Dose: 20 mg Route: intravenous Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/28801850	unhealthy n = 18 Health Status: unhealthy Population Size: 18 Sources: https://pubmed.ncbi.nlm.nih.gov/28801850	Sources: https://pubmed.ncbi.nlm.nih.gov/28801850
200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/28793958	healthy n = 20 Health Status: healthy Sex: M+F Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/28793958	Sources: https://pubmed.ncbi.nlm.nih.gov/28793958
1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	Other AEs: Extrapyramidal disorder... Other AEs: Extrapyramidal disorder Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf
3000 mg single, oral Overdose Dose: 3000 mg Route: oral Route: single Dose: 3000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7779461	unhealthy n = 1 Health Status: unhealthy Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/7779461	Other AEs: Hyperthermia, Mydriasis... Other AEs: Hyperthermia (1 patient) Mydriasis (1 patient) Coma (1 patient) Seizures (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/7779461

AEs

AE	Significance	Dose	Population
Dystonic reaction	2 patients	6 g single, oral Overdose Dose: 6 g Route: oral Route: single Dose: 6 g Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	unhealthy, 29 years (range: 23-40 years) n = 23 Health Status: unhealthy Age Group: 29 years (range: 23-40 years) Sex: M+F Population Size: 23 Sources: https://pubmed.ncbi.nlm.nih.gov/20531221
Bradycardia	24%	6 g single, oral Overdose Dose: 6 g Route: oral Route: single Dose: 6 g Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	unhealthy, 29 years (range: 23-40 years) n = 23 Health Status: unhealthy Age Group: 29 years (range: 23-40 years) Sex: M+F Population Size: 23 Sources: https://pubmed.ncbi.nlm.nih.gov/20531221
Tachycardia	23%	6 g single, oral Overdose Dose: 6 g Route: oral Route: single Dose: 6 g Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	unhealthy, 29 years (range: 23-40 years) n = 49 Health Status: unhealthy Age Group: 29 years (range: 23-40 years) Sex: M+F Population Size: 49 Sources: https://pubmed.ncbi.nlm.nih.gov/20531221
QT interval prolonged	64%	6 g single, oral Overdose Dose: 6 g Route: oral Route: single Dose: 6 g Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	unhealthy, 29 years (range: 23-40 years) n = 49 Health Status: unhealthy Age Group: 29 years (range: 23-40 years) Sex: M+F Population Size: 49 Sources: https://pubmed.ncbi.nlm.nih.gov/20531221
Torsades de pointes	7%	80 g single, oral Overdose Dose: 80 g Route: oral Route: single Dose: 80 g Sources: https://pubmed.ncbi.nlm.nih.gov/20531221	unhealthy, 29 years (range: 23-40 years) n = 49 Health Status: unhealthy Age Group: 29 years (range: 23-40 years) Sex: M+F Population Size: 49 Sources: https://pubmed.ncbi.nlm.nih.gov/20531221
Extrapyramidal disorder		1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf
Coma	1 patient	3000 mg single, oral Overdose Dose: 3000 mg Route: oral Route: single Dose: 3000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7779461	unhealthy n = 1 Health Status: unhealthy Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/7779461
Hyperthermia	1 patient	3000 mg single, oral Overdose Dose: 3000 mg Route: oral Route: single Dose: 3000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7779461	unhealthy n = 1 Health Status: unhealthy Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/7779461
Mydriasis	1 patient	3000 mg single, oral Overdose Dose: 3000 mg Route: oral Route: single Dose: 3000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7779461	unhealthy n = 1 Health Status: unhealthy Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/7779461
Seizures	1 patient	3000 mg single, oral Overdose Dose: 3000 mg Route: oral Route: single Dose: 3000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7779461	unhealthy n = 1 Health Status: unhealthy Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/7779461

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1670 inhibitor 1532 inducer 753	substrate 985 inhibitor 1695	substrate 1168 inhibitor 1789	inhibitor 1570

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2B6 770 CYP2C8 869 CYP2C19 1410 OCT1 498 MATE2 259 OCT2 630 OAT3 625 P-gp 1401 BCRP 678 OATP1B3 691 OAT1 584 OATP1B1 770 MATE1 302 CYP1A2 1463	CYP1A2 1013 CYP2A6 510 CYP2B6 648 CYP2C8 670 CYP2C19 955 CYP2E1 633 P-gp 1491 BCRP 545 MATE2 93 OCT1 317 OATP1B1 389 OATP1B3 333 OAT1 314 OAT3 328 OCT2 336	CYP1A2 671 CYP2B6 521

Drug as perpetrator

Target	Modality	Activity
CYP2D6 1826	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no [IC50 46.1 uM]
BCRP 751	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	no [IC50 >100 uM]
P-gp 1588	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	no [IC50 >100 uM]
CYP1A2 1620	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=179 Page: 179.0	no
CYP1A2 1620	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2B6 946	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=179 Page: 179.0	no
CYP2B6 946	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2C19 1484	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2C8 923	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2C9 1747	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP3A4 1857	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=179 Page: 179.0	no
CYP3A4 1857	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
OAT1 588	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	no
OATP1B1 785	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	no
OATP1B3 700	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	no
OAT3 627	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	weak [Inhibition 100 uM]
OCT2 631	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	weak [Inhibition 100 uM]
MATE2 259	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	yes [IC50 10.1 uM]
OCT1 513	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	yes [IC50 16.1 uM]
MATE1 304	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=87 Page: 87.0	yes

Drug as victim

Target	Modality	Activity
CYP1A2 1013	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2A6 510	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2B6 648	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2C19 955	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2C8 670	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2C9 985	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2D6 1168	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP2E1 633	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
CYP3A4 1670	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=99 Page: 99.0	no
OAT1 314	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	no
OAT3 328	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	no
OATP1B1 389	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	no
OATP1B3 333	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	no
OCT2 336	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=180 Page: 180.0	no
OCT1 317	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=179 Page: 179.0	weak
BCRP 545	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=179 Page: 179.0	yes
MATE2 93	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=179 Page: 179.0	yes
P-gp 1491	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=179 Page: 179.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1603	inhibitor 1584 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf#page=59 Page: 59.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:64045	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:64045
ChemicalBook	CB7312326	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7312326
MolPort	MolPort-003-983-463	https://www.molport.com/shop/molecule-link/MolPort-003-983-463
Selleck Chemicals	Amisulpride	http://www.selleckchem.com/products/Amisulpride.html
eMolecules	1985473	https://www.emolecules.com/cgi-bin/more?vid=1985473

PubMed

Title	Date	PubMed
In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia.	2001 Apr	11270918
Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia.	2001 Dec	11731352
Amisulpride: progress and outcomes.	2002	12418608
Spotlight on amisulpride in schizophrenia.	2002	11888341
Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia.	2002 Dec	12685918
Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders.	2002 Dec	12685917
Atypical antipsychotics: mechanism of action.	2002 Feb	11873706
Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.	2002 Feb	11823257
Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study.	2002 Jan	11800503
Intolerance to neuroleptics and susceptibility for malignant hyperthermia in a patient with proximal myotonic myopathy (PROMM) and schizophrenia.	2002 Jan	11731282
Gateways to clinical trials.	2002 Jan-Feb	11980386
New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update.	2002 Jul	12186270
Effect of the amisulpride isomers on rat prolactinemia.	2002 Jul 19	12144950
The glial growth factors deficiency and synaptic destabilization hypothesis of schizophrenia.	2002 Jul 3	12095426
[Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone].	2002 Jul-Aug	12232542
Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central effect.	2002 Jun 28	12106810
Tardive dyskinesias and antipsychotics: a review.	2002 May	12052573
Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: an evaluation using confirmatory factor analysis.	2002 Sep	12177587
New generation antipsychotics for first episode schizophrenia.	2003	14584012
Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.	2003 Aug	12900302
Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride.	2003 Jan	12515884
The new and evolving pharmacotherapy of schizophrenia.	2003 Mar	12683264
Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization.	2003 Mar	12644990
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].	2003 May	14509051
Metabolic drug interactions with new psychotropic agents.	2003 Oct	14703714
Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality.	2003 Oct	14642970
The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms.	2003 Oct 8	14575800
Response of catatonic schizophrenia to amisulpride: a case report.	2003 Sep	14574833
Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications.	2004	15025545
Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature.	2004 Jan	14750045
Evidence-based pharmacotherapy of schizophrenia.	2004 Jun	15043765
Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study.	2004 Mar	14994321

Patents

Sample Use Guides

In Vivo Use Guide

For acute psychotic episodes, oral doses between 400 mg/d and 800 mg/d are recommended. In individual cases, the daily dose may be increased up to 1200 mg/d. Doses above 1200 mg/d have not been extensively evaluated for safety and therefore should not be used. Doses above 800 mg/d have not been shown to be superior to lower doses and may increase the incidence of adverse events. No specific titration is required when initiating the treatment with amisulpride. Doses should be adjusted according to individual response.

Route of Administration: Oral

In Vitro Use Guide

In NG108-15 cells stably transfected with the human D3 dopamine receptor amisulpride inhibited quinpirole-elicited mitogenesis with an IC50 value of 22 nM

Substance Class	Chemical Created by `admin` on `Sun Dec 18 20:20:17 UTC 2022` Edited by `admin` on `Sun Dec 18 20:20:17 UTC 2022`
Record UNII	8110R61I4U
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AMISULPRIDE

Official Name

English

Amisulpride [WHO-DD]

Common Name

English

APD421

Code

English

BARHEMSYS

Brand Name

English

BENZAMIDE, 4-AMINO-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)-5-(ETHYLSULFONYL)-2-METHOXY-

Systematic Name

English

SULAMID

Brand Name

English

DAN-2163

Code

English

AMISULPRIDE [MI]

Common Name

English

APD-421

Code

English

SOLIAN

Brand Name

English

NSC-760085

Code

English

DENIBAN

Brand Name

English

(±)-AMISULPRIDE

Common Name

English

AMISULPRIDE [EP MONOGRAPH]

Common Name

English

SOCIAN

Brand Name

English

AMISULPRIDE [MART.]

Common Name

English

4-AMINO-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)-5-(ETHYLSULFONYL)-O-ANISAMIDE

Common Name

English

AMISULPRIDE [ORANGE BOOK]

Common Name

English

amisulpride [INN]

Common Name

English

AMINOSULTOPRIDE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66883